Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis
Summary In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months. Introduction T...
Gespeichert in:
| Veröffentlicht in: | Osteoporosis international 2018-07, Vol.29 (7), p.1627-1636 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1636 |
|---|---|
| container_issue | 7 |
| container_start_page | 1627 |
| container_title | Osteoporosis international |
| container_volume | 29 |
| creator | Ebina, K. Hirao, M. Hashimoto, J. Matsuoka, H. Iwahashi, T. Chijimatsu, R. Etani, Y. Okamura, G. Miyama, A. Yoshikawa, H. |
| description | Summary
In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months.
Introduction
The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA).
Methods
A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (
n
= 30), (2) the switch-to-DMAb group (
n
= 30), or (3) the switch-to-TPTD group (
n
= 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months.
Results
After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5;
P
|
| doi_str_mv | 10.1007/s00198-018-4492-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2018666838</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2017545559</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466y-84586956db4875d5753430c6d59553596e3a627cf7eb4806147357490833b09f3</originalsourceid><addsrcrecordid>eNp1kc-K1TAUxoMozp3RB3AjATduqknzr1nK4J-BATcK7kqapre5tElNUqVP5c4X8MU85Y4jCC5CSPL7vnNyPoSeUfKKEqJeZ0KobipCm4pzXVfbA3SgnLGq1lI8RAeimao0p18u0GXOJwIardVjdFFrobig6oB-3syLsQXHAefvvtjRhyOOyUy483kZ476CKS7jEnHvQszrbDogcG_8tOHikl9MMsX3DseAy-jwkuIxuZw9nME3md7DhVlGb_Ep-lDAKJe02rITPuAF5C6UjKGDEQrHKR69rYL59eObw2l0ULNE32OTyph88fkJejSYKbund_sV-vzu7afrD9Xtx_c3129uK8ul3KqGi0ZqIfuON0r0QgnGGbGyF1oIJrR0zMha2UE5IIikXDGYjCYNYx3RA7tCL8--8KevK3Tdzj5bN00muLjmtobZSykb1gD64h_0FNcUoLudUoILITRQ9EzZFHNObmiX5GeTtpaSdg-1PYfagnG7h9puoHl-57x2s-vvFX9SBKA-AxmewtGlv6X_7_obac6xvA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017545559</pqid></control><display><type>article</type><title>Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis</title><source>SpringerLink Journals - AutoHoldings</source><creator>Ebina, K. ; Hirao, M. ; Hashimoto, J. ; Matsuoka, H. ; Iwahashi, T. ; Chijimatsu, R. ; Etani, Y. ; Okamura, G. ; Miyama, A. ; Yoshikawa, H.</creator><creatorcontrib>Ebina, K. ; Hirao, M. ; Hashimoto, J. ; Matsuoka, H. ; Iwahashi, T. ; Chijimatsu, R. ; Etani, Y. ; Okamura, G. ; Miyama, A. ; Yoshikawa, H.</creatorcontrib><description>Summary
In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months.
Introduction
The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA).
Methods
A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (
n
= 30), (2) the switch-to-DMAb group (
n
= 30), or (3) the switch-to-TPTD group (
n
= 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months.
Results
After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5;
P
< 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3;
P <
0.05) and the switch-to-TPTD group (1.7 ± 0.6;
P
< 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (
β
= 0.30, 95% CI = 0.002–0.016;
P <
0.01).
Conclusions
Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-018-4492-y</identifier><identifier>PMID: 29574517</identifier><language>eng</language><publisher>London: Springer London</publisher><subject>Acid phosphatase (tartrate-resistant) ; Bisphosphonates ; Bone mass ; Bone resorption ; Bone turnover ; Drug therapy ; Endocrinology ; Immunotherapy ; Joint diseases ; Medicine ; Medicine & Public Health ; Methotrexate ; Monoclonal antibodies ; Original Article ; Orthopedics ; Parathyroid hormone ; Patients ; Post-menopause ; Prednisolone ; Rheumatoid arthritis ; Rheumatology</subject><ispartof>Osteoporosis international, 2018-07, Vol.29 (7), p.1627-1636</ispartof><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2018</rights><rights>Osteoporosis International is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466y-84586956db4875d5753430c6d59553596e3a627cf7eb4806147357490833b09f3</citedby><cites>FETCH-LOGICAL-c466y-84586956db4875d5753430c6d59553596e3a627cf7eb4806147357490833b09f3</cites><orcidid>0000-0002-2426-1024</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00198-018-4492-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00198-018-4492-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29574517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebina, K.</creatorcontrib><creatorcontrib>Hirao, M.</creatorcontrib><creatorcontrib>Hashimoto, J.</creatorcontrib><creatorcontrib>Matsuoka, H.</creatorcontrib><creatorcontrib>Iwahashi, T.</creatorcontrib><creatorcontrib>Chijimatsu, R.</creatorcontrib><creatorcontrib>Etani, Y.</creatorcontrib><creatorcontrib>Okamura, G.</creatorcontrib><creatorcontrib>Miyama, A.</creatorcontrib><creatorcontrib>Yoshikawa, H.</creatorcontrib><title>Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><addtitle>Osteoporos Int</addtitle><description>Summary
In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months.
Introduction
The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA).
Methods
A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (
n
= 30), (2) the switch-to-DMAb group (
n
= 30), or (3) the switch-to-TPTD group (
n
= 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months.
Results
After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5;
P
< 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3;
P <
0.05) and the switch-to-TPTD group (1.7 ± 0.6;
P
< 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (
β
= 0.30, 95% CI = 0.002–0.016;
P <
0.01).
Conclusions
Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.</description><subject>Acid phosphatase (tartrate-resistant)</subject><subject>Bisphosphonates</subject><subject>Bone mass</subject><subject>Bone resorption</subject><subject>Bone turnover</subject><subject>Drug therapy</subject><subject>Endocrinology</subject><subject>Immunotherapy</subject><subject>Joint diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methotrexate</subject><subject>Monoclonal antibodies</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Parathyroid hormone</subject><subject>Patients</subject><subject>Post-menopause</subject><subject>Prednisolone</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kc-K1TAUxoMozp3RB3AjATduqknzr1nK4J-BATcK7kqapre5tElNUqVP5c4X8MU85Y4jCC5CSPL7vnNyPoSeUfKKEqJeZ0KobipCm4pzXVfbA3SgnLGq1lI8RAeimao0p18u0GXOJwIardVjdFFrobig6oB-3syLsQXHAefvvtjRhyOOyUy483kZ476CKS7jEnHvQszrbDogcG_8tOHikl9MMsX3DseAy-jwkuIxuZw9nME3md7DhVlGb_Ep-lDAKJe02rITPuAF5C6UjKGDEQrHKR69rYL59eObw2l0ULNE32OTyph88fkJejSYKbund_sV-vzu7afrD9Xtx_c3129uK8ul3KqGi0ZqIfuON0r0QgnGGbGyF1oIJrR0zMha2UE5IIikXDGYjCYNYx3RA7tCL8--8KevK3Tdzj5bN00muLjmtobZSykb1gD64h_0FNcUoLudUoILITRQ9EzZFHNObmiX5GeTtpaSdg-1PYfagnG7h9puoHl-57x2s-vvFX9SBKA-AxmewtGlv6X_7_obac6xvA</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Ebina, K.</creator><creator>Hirao, M.</creator><creator>Hashimoto, J.</creator><creator>Matsuoka, H.</creator><creator>Iwahashi, T.</creator><creator>Chijimatsu, R.</creator><creator>Etani, Y.</creator><creator>Okamura, G.</creator><creator>Miyama, A.</creator><creator>Yoshikawa, H.</creator><general>Springer London</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2426-1024</orcidid></search><sort><creationdate>20180701</creationdate><title>Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis</title><author>Ebina, K. ; Hirao, M. ; Hashimoto, J. ; Matsuoka, H. ; Iwahashi, T. ; Chijimatsu, R. ; Etani, Y. ; Okamura, G. ; Miyama, A. ; Yoshikawa, H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466y-84586956db4875d5753430c6d59553596e3a627cf7eb4806147357490833b09f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Acid phosphatase (tartrate-resistant)</topic><topic>Bisphosphonates</topic><topic>Bone mass</topic><topic>Bone resorption</topic><topic>Bone turnover</topic><topic>Drug therapy</topic><topic>Endocrinology</topic><topic>Immunotherapy</topic><topic>Joint diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methotrexate</topic><topic>Monoclonal antibodies</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Parathyroid hormone</topic><topic>Patients</topic><topic>Post-menopause</topic><topic>Prednisolone</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebina, K.</creatorcontrib><creatorcontrib>Hirao, M.</creatorcontrib><creatorcontrib>Hashimoto, J.</creatorcontrib><creatorcontrib>Matsuoka, H.</creatorcontrib><creatorcontrib>Iwahashi, T.</creatorcontrib><creatorcontrib>Chijimatsu, R.</creatorcontrib><creatorcontrib>Etani, Y.</creatorcontrib><creatorcontrib>Okamura, G.</creatorcontrib><creatorcontrib>Miyama, A.</creatorcontrib><creatorcontrib>Yoshikawa, H.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebina, K.</au><au>Hirao, M.</au><au>Hashimoto, J.</au><au>Matsuoka, H.</au><au>Iwahashi, T.</au><au>Chijimatsu, R.</au><au>Etani, Y.</au><au>Okamura, G.</au><au>Miyama, A.</au><au>Yoshikawa, H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis</atitle><jtitle>Osteoporosis international</jtitle><stitle>Osteoporos Int</stitle><addtitle>Osteoporos Int</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>29</volume><issue>7</issue><spage>1627</spage><epage>1636</epage><pages>1627-1636</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>Summary
In biologic-naïve female RA patients, switching oral BPs to DMAb significantly reduced radiographic joint destruction compared to continuing oral BPs or switching to TPTD at 12 months, which were significantly associated with a decrease of a bone resorption marker at 6 months.
Introduction
The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to denosumab (DMAb) or daily teriparatide (TPTD) on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis (RA).
Methods
A retrospective, case-controlled study involving 90 female RA patients (mean age 68.2 years, 96.7% postmenopausal, disease activity score assessing 28 joints with CRP (DAS28-CRP) 2.4, methotrexate treatment 81.1%, prednisolone treatment 68.9%, and prior BP treatment 44.8 months), who were allocated depending on each patient’s and physician’s wishes, to (1) the BP-continue group (
n
= 30), (2) the switch-to-DMAb group (
n
= 30), or (3) the switch-to-TPTD group (
n
= 30), was conducted. Patients were retrospectively selected to minimize the difference of possible clinical backgrounds that may affect the joint destruction of RA. The primary endpoint was to clarify the change of the modified total Sharp score (mTSS) from baseline to 12 months.
Results
After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5;
P
< 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.3 ± 0.2) than in the BP-continue group (1.0 ± 0.3;
P <
0.05) and the switch-to-TPTD group (1.7 ± 0.6;
P
< 0.05). The logistic regression analysis showed that mTSS changes were significantly associated with the percent changes of TRACP-5b at 6 months (
β
= 0.30, 95% CI = 0.002–0.016;
P <
0.01).
Conclusions
Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively.</abstract><cop>London</cop><pub>Springer London</pub><pmid>29574517</pmid><doi>10.1007/s00198-018-4492-y</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-2426-1024</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2018-07, Vol.29 (7), p.1627-1636 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2018666838 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Acid phosphatase (tartrate-resistant) Bisphosphonates Bone mass Bone resorption Bone turnover Drug therapy Endocrinology Immunotherapy Joint diseases Medicine Medicine & Public Health Methotrexate Monoclonal antibodies Original Article Orthopedics Parathyroid hormone Patients Post-menopause Prednisolone Rheumatoid arthritis Rheumatology |
| title | Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T21%3A09%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20switching%20oral%20bisphosphonates%20to%20denosumab%20or%20daily%20teriparatide%20on%20the%20progression%20of%20radiographic%20joint%20destruction%20in%20patients%20with%20biologic-na%C3%AFve%20rheumatoid%20arthritis&rft.jtitle=Osteoporosis%20international&rft.au=Ebina,%20K.&rft.date=2018-07-01&rft.volume=29&rft.issue=7&rft.spage=1627&rft.epage=1636&rft.pages=1627-1636&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-018-4492-y&rft_dat=%3Cproquest_cross%3E2017545559%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017545559&rft_id=info:pmid/29574517&rfr_iscdi=true |